| Literature DB >> 28484502 |
Sirigoon Kuamsub1, Pariyaphat Singthong2, Wipawee Chanthasri1, Nicharee Chobngam1, Warissara Sangkaew3, Sasithorn Hemdecho1, Thammarat Kaewmanee4, Sasitorn Chusri1.
Abstract
Tri-Sura-Phon (TSP), a traditional Thai polyherbal formula renowned for its rejuvenating properties, is commonly used as a blood tonic. It comprises Cinnamomum bejolghota, Cinnamomum parthenoxylon, and Aquilaria crassna. The aim of this study is to evaluate the beneficial properties of TSP tea consumption on blood glucose regulation and serum lipid profiles of healthy overweight volunteers. This open-label, randomized controlled trial was conducted in 70 healthy overweight adults. Two groups of 35 subjects took a TSP infusion or a placebo (cornstarch) twice daily for 8 weeks. The blood glucose regulation, serum lipid profiles, BMI, and liver function tests of the subjects were determined at the baseline, 4th week, and endpoint (8th week). Significant decreases in the average fasting levels of total cholesterol (p = 0.013), triglyceride (p = 0.001), and low-density lipoprotein (LDL, p = 0.017) were observed in the TSP group at the 8th week compared to those at the baseline. The average HDL level in the TSP group at the beginning of the study was 65.2 mg/dL, and it increased significantly (p = 0.005) to 72.4 mg/dL after 8 weeks of TSP intake. This study showed that the intake of TSP tea as an antioxidant-rich beverage might be safe and improve lipid profiles in overweight adults.Entities:
Year: 2017 PMID: 28484502 PMCID: PMC5397647 DOI: 10.1155/2017/2687173
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1A polyherbal formulation, Tri-Sura-Phon, contains equal parts of Aquilaria crassna (a), Cinnamomum parthenoxylon (b), and Cinnamomum bejolghota (c).
Antioxidant capacities and consumer acceptability of Tri-Sura-Phon teas with different brewing times.
| Brewing time (min) | |||
|---|---|---|---|
| 1 | 3 | 5 | |
| Antioxidant capacities | |||
| (i) DPPH radical scavenging capacity | 85.69 ± 1.70a | 89.45 ± 0.63b | 88.49 ± 0.24b |
| (ii) ABTS radical scavenging capacity | 84.52 ± 4.10a | 99.57 ± 0.00b | 100.00 ± 0.00b |
| Sensory analysis | |||
| (i) Colour | 6.60 ± 1.77a | 6.63 ± 1.77a | 6.43 ± 1.87a |
| (ii) Aroma | 5.33 ± 2.17a | 5.53 ± 2.11a | 5.23 ± 2.11a |
| (iii) Taste | 4.73 ± 2.02a | 5.23 ± 2.19a | 5.30 ± 2.89a |
| (iv) Overall acceptability | 4.77 ± 2.13a | 5.30 ± 2.04a | 5.30 ± 1.97a |
The tested teas exhibited DPPH and ABTS radical scavenging activities at concentration of 1% (v/v).
a,bMeans bearing different superscript letters in the same row are significantly different (p < 0.05).
Figure 2CONSORT diagram reflecting flow of study participants through the study.
Effect of Tri-Sura-Phon tea drinking on body mass index, serum lipid profile, glucose and insulin levels, and liver function of healthy overweight volunteers.
| Parameters | Tested group | Mean (SD) | ||
|---|---|---|---|---|
| Baseline | 4th week | 8th week | ||
| BMI (kg/m2) | Tri-Sura-Phon | 27.7 (4.5) | 27.6 (4.5) | 27.6 (4.5) |
| Placebo | 28.3 (4.0) | 28.0 (4.2) | 28.2 (4.1) | |
| Total cholesterol (mg/dL) | Tri-Sura-Phon | 223.7 (37.6) | 213.5 (29.2) | 201.3 (36.2)B |
| Placebo | 210.5 (33.0) | 213.6 (37.2) | 211.9 (42.6) | |
| Triglycerides (mg/dL) | Tri-Sura-Phon | 147.5 (74.3)3 | 79.3 (24.2)A,1,2 | 103.4 (40.2)B,1 |
| Placebo | 142.4 (75.9) | 125.6 (61.5) | 96.1 (37.5)B,C | |
| Low density lipoprotein (mg/dL) | Tri-Sura-Phon | 130.5 (40.5) | 129.7 (30.6) | 108.5 (37.6)B,C,3 |
| Placebo | 116.2 (35.5) | 125.0 (33.7) | 131.7 (44.0) | |
| High density lipoprotein (mg/dL) | Tri-Sura-Phon | 63.4 (12.8) | 68.0 (14.1)3 | 72.4 (13.4)B,1,3 |
| Placebo | 65.8 (10.0) | 67.6 (11.4) | 60.9 (13.6)C | |
| FBG (mg/dL) | Tri-Sura-Phon | 76.2 (6.1)1,2,3 | 84.1 (7.9)A,2,3 | 84.3 (8.4)B,2,3 |
| Placebo | 81.5 (12.0) | 91.4 (12.8)A | 91.2 (9.0)B | |
| Insulin level (uU/mL) | Tri-Sura-Phon | 8.9 (4.1) | 8.3 (3.5)3 | 9.9 (5.0) |
| Placebo | 10.9 (7.0) | 8.7 (4.2) | 10.9 (7.0) | |
| Albumin (gm/dL) | Tri-Sura-Phon | 4.6 (0.5)2 | 4.5 (0.5)2 | 4.1 (0.5)B,C,1,3 |
| Placebo | 4.5 (0.5) | 4.1 (0.4)A | 4.6 (0.5)C | |
| Total bilirubin (mg/dL) | Tri-Sura-Phon | 0.7 (0.4) | 0.9 (0.3)3 | 0.8 (0.4) |
| Placebo | 0.8 (0.5) | 0.9 (0.4) | 0.6 (0.5)C | |
| Direct bilirubin (mg/dL) | Tri-Sura-Phon | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) |
| Placebo | 0.0 (0.2) | 0.0 (0.0) | 0.0 (0.0) | |
| AST (U/L) | Tri-Sura-Phon | 20.1 (5.6)2,3 | 22.6 (6.8) | 19.8 (4.3)2,3 |
| Placebo | 22.7 (7.1) | 24.2 (5.1) | 24.3 (13.2) | |
| ALT (U/L) | Tri-Sura-Phon | 21.1 (14.0)3 | 20.8 (13.4)3 | 18.7 (13.5)3 |
| Placebo | 22.5 (11.6) | 20.7 (11.1) | 30.5 (26.5)C | |
| ALP (U/L) | Tri-Sura-Phon | 78.1 (20.1) | 76.0 (19.5) | 69.6 (21.3) |
| Placebo | 77.5 (15.7) | 74.8 (18.3) | 74.5 (17.0) | |
| GGT (U/L) | Tri-Sura-Phon | 25.0 (15.7) | 25.7 (16.0) | 25.1 (17.7) |
| Placebo | 25.5 (8.6) | 23.0 (8.3) | 26.0 (12.2) | |
Uppercase superscript letters indicate the significant differences in parameters between the baseline and week 4 (A) or the baseline and week 8 (B) or weeks 4 and 8 (C) within the treatment.
Superscript numbers indicate the significant differences between the parameters at baseline (1), week 4 (2), or week 8 (3) among the treatments.
BMI = body mass index, FBG = fasting blood glucose, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALP = alkaline phosphatase, and GGT = gamma-glutamyl transpeptidase.
Changes in clinical laboratory parameters after the consumption of Tri-Sura-Phon tea.
| Parameters | Tested groups | Changes of evaluated values (SD) | ||
|---|---|---|---|---|
| wk. 0 | wk. 0 | wk. 4th | ||
| BMI (kg/m2) | Tri-Sura-Phon | 0.1 (0.4)3 | 0.1 (0.5)3 | 0.0 (0.3)1 |
| Placebo | 0.3 (0.5) | 0.1 (0.7) | −0.2 (0.5)A,B | |
| Total cholesterol (mg/dL) | Tri-Sura-Phon | 10.1 (34.0) | 22.4 (42.4)1,2,3 | 12.2 (22.3) |
| Placebo | −3.2 (33.2) | −1.5 (29.8) | 1.7 (29.6) | |
| Triglycerides (mg/dL) | Tri-Sura-Phon | 68.2 (79.3)1,3 | 44.1 (80.8) | −24.1 (47.3)A,B,1,2,3 |
| Placebo | 16.8 (97.7) | 46.3 (76.5) | 29.5 (57.7) | |
| Low density lipoprotein (mg/dL) | Tri-Sura-Phon | 0.9 (38.8) | 22.1 (49.2)A,1,2,3 | 21.18 (26.7)A,1,2,3 |
| Placebo | −8.9 (36.0) | −15.5 (38.9) | −6.7 (35.2) | |
| High density lipoprotein (mg/dL) | Tri-Sura-Phon | −4.6 (13.3)2,3 | −9.0 (15.3)1,2,3 | −4.4 (11.8)2,3 |
| Placebo | −1.8 (12.6) | 4.9 (12.7) | 6.7 (14.9)A | |
| FBG (mg/dL) | Tri-Sura-Phon | −7.8 (7.8)3 | 8.1 (7.0)3 | −0.3 (7.2)A,B,1,2 |
| Placebo | −10.0 (7.7) | −9.7 (8.1) | 0.2 (8.3)A,B | |
| Insulin level (uU/mL) | Tri-Sura-Phon | 0.5 (4.0) | −1.0 (4.6) | −1.7 (4.4) |
| Placebo | −0.2 (5.9) | −2.4 (8.2) | −2.0 (7.7) | |
| Albumin (gm/dL) | Tri-Sura-Phon | 0.1 (0.4)3 | 0.4 (0.7)A,2,3 | 0.1 (0.5)B,2 |
| Placebo | 0.2 (0.5) | 0.0 (0.2) | −0.3 (0.5)A | |
| Total bilirubin (mg/dL) | Tri-Sura-Phon | 0.0 (0.2) | 0.0 (0.0)2,3 | 0.1 (0.3) |
| Placebo | 0.0 (0.2) | 0.1 (0.3)A | 0.1 (0.4)A | |
| Direct bilirubin (mg/dL) | Tri-Sura-Phon | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) |
| Placebo | 0.0 (0.2) | 0.0 (0.2) | 0.0 (0.0) | |
| AST (U/L) | Tri-Sura-Phon | −2.5 (7.2) | 0.2 (5.3) | 2.8 (5.2)A,1,2 |
| Placebo | −1.5 (7.4) | −1.6 (9.8) | −0.1 (13.4) | |
| ALT (U/L) | Tri-Sura-Phon | 0.3 (10.2)2,3 | 2.3 (11.4)2,3 | 2.0 (7.7)2,3 |
| Placebo | 1.8 (8.9) | −7.9 (24.1)A | −9.7 (23.9)A | |
| ALP (U/L) | Tri-Sura-Phon | 2.1 (9.3) | 8.6 (12.4)A,3 | 6.4 (11.2) |
| Placebo | 2.7 (15.1) | 3.0 (11.4) | 0.36 (16.8) | |
| GGT (U/L) | Tri-Sura-Phon | −0.7 (9.4) | −0.1 (8.7) | 0.6 (4.1) |
| Placebo | 2.5 (5.1) | −0.5 (8.5) | −3.0 (9.6)A | |
Uppercase superscript letters indicate significant differences in changes of parameters between baseline and week 4 (A) or baseline and week 8 (B) or weeks 4 and 8 (C) in the same treatment.
Superscript numbers indicate significant differences in changes of parameters between baseline and week 4 (1) or baseline and week 8 (2) or weeks 4 and 8 (3) among the treatments.
Negative values correspond to increases from baseline and positive values correspond to decreases from baseline.
BMI = body mass index, FBG = fasting blood glucose, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALP = alkaline phosphatase, and GGT = gamma-glutamyl transpeptidase.